Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

With psoriasis, the most commonly elevated cytokines ... Other medications require less frequent injections after the initial dose, such as Cosentyx and Taltz every four weeks, Simponi once ...